695 participants
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2018-12-31
- Start Date:
- 2014-09-04
- Completion:
- 2016-04-26
Conditions
- Diabetes Mellitus
Interventions
- DRUG